{"title":"联合SGLT-2抑制剂和glp -1受体激动剂降低2型糖尿病心血管风险","authors":"H. Krumholz, Sm","doi":"10.1056/NEJM-JW.NA54310","DOIUrl":null,"url":null,"abstract":"There is much excitement about the emerging evidence on sodium–glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)–receptor","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combining SGLT-2 Inhibitors and GLP-1–Receptor Agonists for CV Risk Reduction in Type 2 Diabetes\",\"authors\":\"H. Krumholz, Sm\",\"doi\":\"10.1056/NEJM-JW.NA54310\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There is much excitement about the emerging evidence on sodium–glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)–receptor\",\"PeriodicalId\":19048,\"journal\":{\"name\":\"NEJM Journal Watch\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NEJM Journal Watch\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1056/NEJM-JW.NA54310\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEJM Journal Watch","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/NEJM-JW.NA54310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Combining SGLT-2 Inhibitors and GLP-1–Receptor Agonists for CV Risk Reduction in Type 2 Diabetes
There is much excitement about the emerging evidence on sodium–glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)–receptor
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
